Clinical trial / 2005
Shark cartilage failed to improve overall survival or quality of life in advanced cancer.
In a randomized double-blind trial, 83 evaluable patients with advanced, incurable breast or colorectal cancer received standard care combined with either a shark cartilage supplement or placebo three to four times daily. Shark cartilage did not improve overall survival compared with placebo. Furthermore, the intervention showed no benefit for quality of life, failing to demonstrate efficacy in this patient population.
- Study type
- Randomized controlled trial
- Who was studied
- 83 evaluable patients with advanced breast or colorectal cancer
- What was measured
- Overall survival and quality of life
THE PAPER
Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial.
Loprinzi CL, Levitt R, Barton DL, Sloan JA, Atherton PJ, Smith DJ, Dakhil SR, Moore DF, Krook JE, Rowland KM, Mazurczak MA, Berg AR, Kim GP, North Central Cancer Treatment Group. Cancer, 2005.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.